Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-4324 in Overweight to Obese Healthy Volunteers and T2DM Patients
NCT06845202Phase 2Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of ALN-4324 in type 2 diabetes mellitus (T2DM), obesity, sponsored by Alnylam Pharmaceuticals. Started Mar 2025; status: active, not recruiting.
02
Drugs
ALN-4324
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06845202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845202.